Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (72057)	12/17/1999 9:55:00 PM
From: Gary Mohilner	Respond to of 132070

With all the warrants, preferred, etc they'll be up to about 35 million shares. The market for their initial drug is in the billions if it works on multiple cancers, and it's a billion dollar drug if limited to one. We know the royalties from SBH are in excess of 10%. While the earnings will be great on drug approval, I'm more excited about what could happen in less then 6 months, proven efficacy. Once efficacy's determined, the potential of IMGN TAP technology will be established. I believe at that point numerous major biotechs and pharmas will be looking to partner with IMGN to turn MAB's they own into cancer killing drugs. With several partnerships generating milestone payments routinely, IMGN will be generating substantial income without an approved drug. Gary